Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00374582 · ClinicalTrials.gov registry record · NA

End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)

A NA study of End Stage Liver DIsease, sponsored by University of Cincinnati.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT00374582: Completed NA study of End Stage Liver DIsease, sponsored by University of Cincinnati.

NCT00374582 is a NA study of End Stage Liver DIsease that has completed, run by University of Cincinnati. The registered enrollment target is 30 participants, below the 489-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00374582, a NA study of End Stage Liver DIsease, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to see how effective bioelectric impedance analysis (BIA) is in determining body composition (the amount of fat versus muscle in the body) and nutritional status in patients with End Stage Liver Disease (ESLD)

Conditions Studied

Interventions

  • DEVICE Bodystat Quadscan 4000
  • DEVICE bodystat quadscan 400

Study Locations (1)

Ohio

  • University of Cincinnati - Cincinnati

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2006-09
Est. Completion 2008-05
Phase NA
University of Cincinnati

245 total trials

What the finished NCT00374582 record still lists

NCT00374582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 489-participant average among 16 other End Stage Liver DIsease trials with a reported enrollment target (94% lower).

The record links to 1 condition, with End Stage Liver DIsease appearing as the primary indexed condition, and to 2 interventions - of which Bodystat Quadscan 4000 is the first listed.

NCT00374582 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00374582 about?

NCT00374582 is a clinical study titled "End Stage Liver Disease and Body Composition Assessment: Utilizing Bioelectric Impedance Analysis (BIA)". The purpose of this research study is to see how effective bioelectric impedance analysis (BIA) is in determining body composition (the amount of fat versus muscle in the body) and nutritional status in patients with End Stage Liver Disease (ESLD)

What is the current status of trial NCT00374582?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2008-05.

What conditions does trial NCT00374582 study?

This clinical trial studies the following conditions: End Stage Liver DIsease.

What interventions are being tested in trial NCT00374582?

The interventions under investigation include: Bodystat Quadscan 4000 (DEVICE), bodystat quadscan 400 (DEVICE).

Who is sponsoring clinical trial NCT00374582?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00374582 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Liver DIsease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00374582's enrollment target sits among peer trials

30 13th of 16 higher than 3 of 16 other End Stage Liver DIsease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other End Stage Liver DIsease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00374582, the US trial registry maintained by the National Library of Medicine. NCT00374582 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.